DK2521776T3 - Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenoviralt middel - Google Patents

Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenoviralt middel Download PDF

Info

Publication number
DK2521776T3
DK2521776T3 DK11731733.9T DK11731733T DK2521776T3 DK 2521776 T3 DK2521776 T3 DK 2521776T3 DK 11731733 T DK11731733 T DK 11731733T DK 2521776 T3 DK2521776 T3 DK 2521776T3
Authority
DK
Denmark
Prior art keywords
seq
wild type
set forth
sequence set
copy
Prior art date
Application number
DK11731733.9T
Other languages
English (en)
Inventor
Yael Cohen
Naamit Sher
Erez Feige
Livnat Bangio
Eyal Breitbart
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of DK2521776T3 publication Critical patent/DK2521776T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (20)

  1. FREMGANGSMÅDER TIL ANVENDELSE AF ET SPECIFIKT ANTI-ANGIOGENT ADENOVIRALT MIDDEL
    1. Adenovirusvektor til anvendelse i behandling af en solid tumor hos et menneske med behov derfor, hvor vektoren omfatter et polynukleotid, der omfatter et fas-ehimera-transgen, der transskriptionsmæssigt er bundet til en PPE-1 -3X-promoter, og hvor vektoren skal administreres til personen ved en terapeutisk effektiv mængde på 3 X 1012 eller 1 X 1013 viruspartikler,
  2. 2. Adenovi rusvektoren for anvendelse ifølge krav 1, hvor vektoren skal administreres i mindst to separate doser.
  3. 3. Adenovirusvektoren for anvendelse ifølge krav 1 eller 2, hvor den terapeutisk effektive mængde er 1 X 1G13 viruspartikler.
  4. 4. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 ti! 3, hvor den solide tumor er en cancer, en primær tumor eller en metastaserende tumor.
  5. 5. Adenovirusvektor ti! anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor den solide tumor er en thyreoideacancer eller en neuroendokrin cancer.
  6. 6. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor adenovirusvektoren skal administreres systemisk.
  7. 7. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor fas-chimera-transgenel omfatter et polynukleotid med nukieotidsekvensen ifølge SEQ ID NO: 2 og SEQ ID NO: 3 eller nukieotidsekvensen ifølge SEQ ID NO: 4.
  8. 8. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor PPE-1 -3X-promoteren omfatter et polynukleotid med (i) nukieotidsekvensen ifølge SEQ ID NO: 8 eiler den komplementære sekvens deraf, (ii) nukieotidsekvensen iføige SEQ ID NO: 8 eller den komplementære sekvens deraf og nukieotidsekvensen iføige SEQ ID NO: 6 eller den komplementære sekvens deraf, (iii) nukieotidsekvensen ifølge SEQ ID NO: 7 eller en komplementær sekvens deraf eller (iv) nukieotidsekvensen ifølge SEQ ID NO: 12.
  9. 9. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor adenovirusvektoren er en adenovi ru s-5-vektor.
  10. 10. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor adenovirusvektoren omfatter nukleinsyresekvensen ifølge SEQ ID NO: 9 eller 10,
  11. 11. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor personen endvidere skal modtage et kemoterapeutisk middel.
  12. 12. Adenovirusvektor for anvendelse ifølge krav 11, hvor det kemoterapeutiske middel skal administreres forud for behandling med viruspartiklerne, samtidig med behandling med virus partiklerne eller efter behandling med viruspartiklerne.
  13. 13. Adenovirusvektor for anvendelse ifølge krav 11, hvor det kemoterapeutiske middel er sunitinib.
  14. 14. Adenovirusvektor til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor vektoren er formuleret som en farmaceutisk sammensætning.
  15. 15. Adenovirusvektor til anvendelse iføige et hvilket som helst af kravene 1 til 14, hvor vektoren reducerer sygdomsprogression via den soiide tumor hos personen.
  16. 16. Adenovirusvektor ti! anvendelse ifølge et hvilket som helst af kravene 1 til 15, hvor den solide tumor er en thyreoideacancer.
  17. 17. Anvendelse af en adenovirusvektor i fremstilling af et medikament tii behandling af en solid tumor hos et menneske med behov derfor, hvor vektoren omfatter et polynukleotid, der omfatter et fas-chimera-transgen, der transskriptionsmæssigt er bundet tii en PPE-1-3X-promoter, og hvor medikamentet omfatter 3 X 1012 eller 1 X 1013 viruspartikler.
  18. 18. Anvendelse ifølge krav 17, hvor fas-chimera-transgenet omfatter et polynukleotid med nukleotidsekvensen ifølge SEQ ID NO: 2 og SEQ ID NO: 3 eller nukleotidsekvensen ifølge SEQ ID NO: 4 og/eiier PPE-1-3X-promoteren omfatter et polynukleotid med (i) nukleotidsekvensen ifølge SEQ ID NO: 8 eller den komplementære sekvens deraf, (ii) nukleotidsekvensen ifølge SEQ ID NO: 8 eller den komplementære sekvens deraf og nukleotidsekvensen ifølge SEQ ID NO: 6 eller den komplementære sekvens deraf, (iii) nukleotidsekvensen ifølge SEQ ID NO: 7 eller en komplementær sekvens deraf eller (iv) nukleotidsekvensen ifølge SEQ ID NO: 12.
  19. 19. Anvendelse ifølge krav 17 eller 18, hvor adenovirusvektoren er en adenovirus-5-vektor.
  20. 20. Anvendelse ifølge et hvilket som helst af kravene 17 til 19, hvor den solide tumor er en thyreoideacancer.
DK11731733.9T 2010-01-05 2011-01-05 Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenoviralt middel DK2521776T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28222810P 2010-01-05 2010-01-05
US28224710P 2010-01-07 2010-01-07
PCT/IL2011/000007 WO2011083464A2 (en) 2010-01-05 2011-01-05 Methods for use of a specific anti-angiogenic adenoviral agent

Publications (1)

Publication Number Publication Date
DK2521776T3 true DK2521776T3 (da) 2017-02-13

Family

ID=44305892

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16196233.7T DK3159405T3 (da) 2010-01-05 2011-01-05 Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenovirusmiddel
DK11731733.9T DK2521776T3 (da) 2010-01-05 2011-01-05 Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenoviralt middel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16196233.7T DK3159405T3 (da) 2010-01-05 2011-01-05 Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenovirusmiddel

Country Status (11)

Country Link
US (3) US9567605B2 (da)
EP (2) EP2521776B1 (da)
JP (2) JP6196040B2 (da)
KR (1) KR101754437B1 (da)
AU (1) AU2011204405B2 (da)
CA (1) CA2786374C (da)
DK (2) DK3159405T3 (da)
MX (1) MX342641B (da)
NZ (1) NZ601324A (da)
SG (2) SG182367A1 (da)
WO (1) WO2011083464A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
EP2051988A4 (en) 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
PL2908865T3 (pl) * 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3223824B1 (en) 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
JP2021500355A (ja) * 2017-10-20 2021-01-07 バスキュラー バイオジェニックス リミテッド 抗血管新生薬剤療法のための診断方法
US10525127B2 (en) * 2018-03-31 2020-01-07 Femtomab P14.7 protein and uses thereof as vaccine adjuvant
WO2019239216A2 (en) * 2018-06-13 2019-12-19 The Council Of The Queensland Institute Of Medical Research Viral detection assay
KR20210139329A (ko) 2019-03-13 2021-11-22 바스큘라 바이오제닉스 리미티드 항종양 요법의 방법
MX2021012398A (es) 2019-04-12 2021-11-12 Vascular Biogenics Ltd Metodos de terapia antitumoral.

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
AU5178800A (en) 1999-06-01 2000-12-18 Cornell Research Foundation Inc. Activation of dendritic cells to enhance immunity
IL130608A0 (en) * 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
ES2425321T3 (es) 2000-11-17 2013-10-14 Vascular Biogenics Ltd. Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
AU2003296663A1 (en) * 2002-12-18 2004-07-09 Novartis Ag Endothelial cell specifically binding peptides
CA2557326A1 (en) 2004-02-24 2005-09-09 Introgen Therapeutics, Inc. Combination of ad-p53 and chemotherapy for the treatment of tumours
EP1786904A4 (en) 2004-08-09 2010-06-16 Merck Sharp & Dohme Adenovirus vector COMPOSITIONS
US20090232808A1 (en) 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
EP2051988A4 (en) 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
JP6009357B2 (ja) 2010-01-12 2016-10-19 バスキュラー バイオジェニックス リミテッド アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物
PL2908865T3 (pl) 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka

Also Published As

Publication number Publication date
AU2011204405A1 (en) 2012-08-30
WO2011083464A2 (en) 2011-07-14
KR20130139741A (ko) 2013-12-23
JP2013516454A (ja) 2013-05-13
EP3159405B8 (en) 2018-11-07
SG10201500013SA (en) 2015-03-30
US9567605B2 (en) 2017-02-14
NZ601324A (en) 2014-10-31
EP2521776A2 (en) 2012-11-14
WO2011083464A3 (en) 2011-11-10
JP2017186341A (ja) 2017-10-12
US20130280216A1 (en) 2013-10-24
US20130280217A1 (en) 2013-10-24
MX2012007849A (es) 2012-10-09
DK3159405T3 (da) 2019-01-07
EP3159405B1 (en) 2018-09-12
CA2786374A1 (en) 2011-07-14
EP3159405A1 (en) 2017-04-26
KR101754437B1 (ko) 2017-07-05
EP2521776B1 (en) 2016-11-02
US20140010785A1 (en) 2014-01-09
SG182367A1 (en) 2012-08-30
EP2521776A4 (en) 2013-07-31
AU2011204405B2 (en) 2015-06-18
MX342641B (es) 2016-10-07
JP6196040B2 (ja) 2017-09-13
CA2786374C (en) 2019-01-22

Similar Documents

Publication Publication Date Title
DK2521776T3 (da) Fremgangsmåder til anvendelse af et specifikt anti-angiogent adenoviralt middel
KR101810257B1 (ko) 아교모세포종 ｇｂｍ을 치료하기 위한 조성물 및 방법
AU2018271398B2 (en) Treatment methods using adenovirus
KR101396454B1 (ko) 내피 세포 특이성을 나타내는 프로모터 및 이를 이용하여 혈관신생을 조절하는 방법
KR20200140848A (ko) 복제 속성이 향상된 종양살상형 아데노바이러스 조성물
KR20210152504A (ko) 항종양 요법의 방법
KR20210139329A (ko) 항종양 요법의 방법
HK40028530A (en) Oncolytic adenoviral vector and adoptive t-cell therapeutic composition and use thereof
CN111356480A (zh) 用于抗血管生成剂疗法的诊断方法